脉冲降低剂量率再照射治疗复发性乳腺癌
结果显示,大体肿瘤患者完全缓解率83.3%,1年和2年局部区域无复发生存率分别为81.3%和73.8%,局限性病变患者1年和2年总生存率分别为95.7%和91.1%;急性3级放射性皮炎发生率25.6%,3级晚期毒性发生率18.6%。结论认为PRDR联合卡培他滨耐受性好且有效,需前瞻性研究进一步比较。
要点
- PRDR再照射中位剂量54 Gy,中位累积剂量109.8 Gy,同步卡培他滨多为500 mg每日两次。
- 大体肿瘤完全缓解率83.3%,1年和2年局部区域无复发生存率分别为81.3%和73.8%。
- 急性3级放射性皮炎发生率25.6%,3级晚期毒性发生率18.6%,无其他急性3级毒性。
核心结论
- PRDR放疗联合卡培他滨是治疗复发性乳腺癌耐受性好且有效的方法。
- 需要前瞻性研究比较其副作用和疗效与常规剂量率再照射的差异,并评估卡培他滨在复发设置中的潜在作用。
研究设计与样本
- 再照射中位剂量54 Gy(范围37.5-66 Gy),表观剂量率6.67 cGy/min,中位累积剂量109.8 Gy。
- 采用Kaplan-Meier法进行生存分析,Cox回归进行单因素和多因素分析。
主要发现
- 有大体肿瘤的受治患者完全缓解率为83.3%。
- 所有患者1年和2年局部区域无复发生存率分别为81.3%和73.8%。
- 局限性病变患者1年和2年总生存率分别为95.7%和91.1%。
- 急性3级放射性皮炎发生率为25.6%,无其他急性3级毒性;3级晚期毒性发生率为18.6%。
临床怎么用
- 对于既往照射野内局部区域复发的乳腺癌患者,可考虑采用PRDR放疗再照射以增加治疗比。
- PRDR再照射时可同步低剂量卡培他滨(如500 mg每日两次),但需关注急性3级放射性皮炎和晚期毒性。
局限性
- 缺乏与常规剂量率再照射的对照比较,卡培他滨的作用需前瞻性研究评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Locoregionally recurrent breast cancer within a previously irradiated field requires weighing the benefits of reirradiation against the increased rates of toxicity. Here we evaluate the outcomes of patients treated with pulsed reduced dose rate (PRDR) radiation therapy with concurrent low-dose capecitabine as a method to increase the therapeutic ratio of re-treatment. METHODS AND MATERIALS: Patients treated from November 2000 to June 1, 2018 with PRDR radiation therapy at University of Wisconsin were identified. Patients were re-treated to a median dose of 54 Gy (range, 37.5-66 Gy) using PRDR radiation therapy, delivering radiation at an apparent dose rate of 6.67 cGy/min to allow for increased sublethal damage repair of normal tissues. The median cumulative dose was 109.8 Gy. Twenty-two patients were treated with concurrent capecitabine, most frequently at 500 mg twice per day. The Kaplan-Meier method was used for survival analysis, and Cox regression analysis was used for univariate and multivariate analysis. RESULTS: Forty-three patients were identified who underwent reirradiation for locoregionally recurrent invasive breast cancer, with a median follow-up of 20.5 months. Twenty-four patients had gross disease. Nineteen patients had simultaneous metastatic disease. The complete response rate was 83.3% in treated patients with gross disease. Locoregional recurrence-free survival was 81.3% and 73.8% for all patients at 1 and 2 years, respectively. Overall survival for patients with localized disease was 95.7% at 1 year and 91.1% at 2 years. The rate of acute grade 3 radiation dermatitis was 25.6% with no other acute grade 3 toxicities. Grade 3 late toxicity occurred in 18.6% of patients. CONCLUSIONS: PRDR radiation therapy with capecitabine was a well-tolerated and effective method for treating patients with recurrent breast cancer. Prospective studies are necessary to compare side effects and efficacy with conventional dose rate reirradiation and to evaluate the potential role for capecitabine in the recurrent setting.
引用
- Burr AR, Robins HI, Bayliss RA, et al. Pulsed Reduced Dose Rate for Reirradiation of Recurrent Breast Cancer. Pract Radiat Oncol. 2019. PMID: 31526900. doi:10.1016/j.prro.2019.09.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。